Production Of Attenuated Chimeric Respiratory Syncytial Virus Vaccines From Cloned Nucleotide Sequences


Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.

Download PDF
Document Preview
Document History
  • Publication: Feb 10, 2004
  • Application: Apr 13, 1999
    US US 29189499 A
  • Priority: Apr 13, 1999
    US US 29189499 A
  • Priority: Jul 15, 1997
    US US 89240397 A
  • Priority: May 23, 1997
    US US 4763497 P
  • Priority: May 9, 1997
    US US 4614197 P
  • Priority: Sep 27, 1996
    US US 72013296 A
  • Priority: Jul 15, 1996
    US US 2177396 P
  • Priority: Sep 27, 1995
    US US 708395 P

Download Citation

Sign in to the Lens